rituximab   

GtoPdb Ligand ID: 6780

Synonyms: HSDB 7455 | IDEC-C2B8 | MabThera® | Rituxan®
rituximab is an approved drug (FDA (1997), EMA (1998))
Compound class: Antibody
Comment: Rituximab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes. It is a cancer and autoimmune disease drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
NameTrade nameCompanyClinical PhaseIndications
CT-P10; rituximab-abbsBlitzima; Truxima; Tuxella (renamed Rituenza); RitemviaCelltrionApproved (EMA 2017, FDA 2018)Non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and severe rheumatoid arthritis (Truxima only). Rituenza's marketing authorisation withdrawn in EU in 2017 at Celltrion's request.
PF-05280586; rituximab-pvvrRuxience PfizerApproved (FDA 2019)NHL, CLL, GPA, MPA
BCD-020AcellBiaBiocadApproved in 2014 by the Ministry of Health of the Russian Federation; Ph 3 trials elsewhere- see NCT02744196 and NCT01759030 as examplesRheumatoid arthritis
GP2013Rixathon; RiximyoSandozApproved (EMA 2017) NHL, CLL
SAIT101 Archigen BiotechPh 3 comparision clinical trial with MabThera® for follicular lymphoma (NCT02809053), and Ph 1 NCT02819726 for rheumatoid arthritisRheumatoid arthritis, follicular lymphoma
ABP 798 AmgenPh 3 (NCT02747043; NCT02792699)Rheumatoid arthritis, NHL
BI 695500 Boehringer IngelheimDevelopment halted at Ph 3 (NCT02417129)NHL
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: rituximab

Immunopharmacology Comments
Rituximab is the first biological agent to show positive effects on biological and clinical disease parameters in Sjögren's syndrome [1,7].
Immunopharmacology Disease
Disease X-Refs Comment References
Chronic lymphocytic leukemia Disease Ontology: DOID:1040
OMIM: 151400
Orphanet: ORPHA67038
An anti-CD20 therapy approved for CLL and non-Hodgkins lymphoma.
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
An anti-CD20 therapy approved for RA.
Pemphigus Disease Ontology: DOID:9182
Rituximab is the first biologic therapy approved for pemphigus vulgaris (PV), and represents the first major PV therapeutic advance in more than 60 years.
Immunopaedia Case Studies Links
My eyes cross at twilight
A 7 year old with severe muscle weakness and difficulty walking
A case of lymphadenopathy and night sweats
My head hurts and I cannot speak?